Global automotive sensors market was valued at $37.2 billion in 2025 and is growing at a CAGR of 8.1% during the forecast period (2026-2035). Pressure sensors play an essential role in automotive systems by monitoring tire, engine, and fluid pressures in real time. They enhance vehicle safety, optimize performance, and support predictive maintenance. Integration with wireless and connected systems enables efficient data sharing, reduces hardware complexity, and contributes to lower maintenance costs.

BRICS e-commerce logistics market was valued at $183.3 billion in 2025 and is projected to reach $525.2 billion by 2035, growing at a CAGR of 12.4% during the forecast period (2026–2035). The rapid acceleration of mobile-led e-commerce adoption across BRICS markets, particularly India, is directly strengthening demand in the BRICS e-commerce logistics market by driving higher order volumes and delivery frequency. Analysis by Affle’s MAAS platform and Sensor Tower indicates sustained growth in daily active users on shopping apps in India, with the top 10 platforms averaging over 7 million daily active users each in Q2 2021, reflecting an 18% year-on-year increase. This expansion in user engagement translates into a consistent rise in transaction volumes, requiring scalable logistics capabilities across last-mile delivery, warehousing, and order fulfillment. Increased app usage also shortens purchase cycles, intensifying demand for faster and more reliable logistics networks across urban and semi-urban areas.

Asia-Pacific Osteoarthritis Therapeutics market was valued at $2,744.0 million in 2025 and is projected to reach $6,285.0 million by 2035, growing at a CAGR of 8.2% during the forecast period (2026–2035). Expansion of local pharmaceutical manufacturing capacity in key Asia-Pacific markets such as China and India is strengthening drug availability, lowering treatment costs, and directly supporting growth in the osteoarthritis therapeutics market. According to the Ministry of Commerce and Industry, India’s pharmaceuticals industry reached approximately $57 billion in annual turnover in 2023.  Government initiatives such as India’s Production-Linked Incentive (PLI) scheme for pharmaceuticals and emphasis on self-sufficiency in essential medicines have accelerated local API and biologic output, improving regional supply chain resilience and reducing dependence on imports.

Asia-Pacific High-Performance Liquid Chromatography (HPLC) market was valued at $1,471.3 million in 2025 and is projected to reach $2,357.6 million by 2035, growing at a CAGR of 4.2% during the forecast period (2026-2035). The market is witnessing significant technological advancements that are expanding analytical capabilities and improving laboratory efficiency. Manufacturers are introducing ultra-high-pressure liquid chromatography (UHPLC) systems that deliver faster separations with higher resolution and lower solvent use compared with traditional HPLC platforms. Recent launches include next-generation detectors such as multi-wavelength UV, charged aerosol detectors, and interfaces compatible with mass spectrometry, enabling broader analyte detection and improved quantitative accuracy in complex sample matrices. Companies are also advancing core-shell and superficially porous particle column chemistries that enhance peak capacity and sensitivity, particularly for pharmaceutical and environmental testing applications.

US HPLC market was valued at $1,848.4 million in 2025 and is expected to reach $2,763.9 million by 2035, registering a CAGR of 4.2% over the forecast period from 2026 to 2035. The rapid expansion of biologics and complex therapeutic development in the US is a key driver of HPLC demand, particularly for advanced analytical characterization and quality control applications. In 2024, the US Food and Drug Administration approved 50 new therapies, including small molecules and biologics, marking one of the highest annual totals of novel drug approvals on record. This indicates that biologics represent a growing share of these approvals, with recent years averaging double-digit biologic approvals annually, particularly monoclonal antibodies and protein therapeutics.

North America Osteoarthritis Therapeutics market was valued at $4,256.0 million in 2025 and is projected to reach $9,551.3 million by 2035, growing at a CAGR of 8.2% during the forecast period (2026–2035). The availability and widespread clinical adoption of established pharmacologic therapies form a core demand driver for the North American osteoarthritis therapeutics market. NSAIDs, corticosteroids, and opioid analgesics remain integral to osteoarthritis treatment algorithms across early, moderate, and advanced disease stages. Their long-standing regulatory approval and inclusion in clinical guidelines support consistent prescribing across primary care, orthopedics, and pain management settings. As osteoarthritis is a chronic and progressive condition, patients often require sustained pharmacologic intervention over extended periods, reinforcing recurring demand. The broad use of first-line oral therapies ensures a stable treatment base, anchoring overall market size and baseline revenue generation.

Global waterjet cutting machines market was valued at $1.5 billion in 2025 and is growing at a CAGR of 4.4% during the forecast period (2026-2035). Technological advancements in cutting head design and pressure control enhance cutting efficiency, enabling manufacturers to work with diverse materials while achieving superior edge quality and minimizing secondary finishing requirements, thereby fostering market growth. For instance, in July 2024, WECJet invested in a new Mach 500 waterjet cutting machine, which utilizes advanced 90000psi Dynamic head cutting technology, making it the fastest waterjet currently available in the global market. This new acquisition enhances WECJet's capabilities, allowing them to cut various materials up to 300mm thick and 3m wide, thanks to an enlarged bed and increased open height for large parts. The company maintains an extensive inventory of materials, including MS/S355, 304, 316 stainless steel, and aluminum in standard thicknesses. Their round-the-clock operations ensure competitive lead times and a 48-hour turnaround for stock materials

Global skin cancer diagnosis and therapeutics market was valued at $14.0 billion in 2025 and is growing at a CAGR of 6.1% during the forecast period (2026-2035). Regulatory approval of the first cell therapy for solid tumors marks a milestone in oncology, broadening treatment avenues from solely hematological cancers to include advanced skin cancers. This development endorses tumor-infiltrating lymphocyte (TIL) approaches, thereby encouraging greater clinical implementation and facilitating market growth through the expansion of treatment pipelines. For instance, in February 2024, FDA approved lifileucel, the first cancer cell therapy for solid tumors, specifically for advanced melanoma. This one-time T-cell therapy, manufactured by Iovance Biotherapeutics and branded as Amtagvi, is indicated for adults with unresectable or metastatic melanoma who have previously received PD-1 inhibitors and, if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor.

Global PET-CT market was valued at $2.4 billion in 2025 and is growing at a CAGR of 4.0% during the forecast period (2026-2035). The growing preference for whole-body, single-session imaging is driving the adoption of next-generation PET-CT systems, which enable comprehensive scans from head to thigh in a single acquisition. This enhances diagnostic confidence and improves patient throughput, thereby contributing to market growth. For instance, in November 2025, GE HealthCare received CE Mark approval for its Omni 128cm total body PET/CT system, aimed at enhancing cancer diagnosis and treatment planning. This system offers head-to-thigh imaging in one session, optimizing workflow and reducing scan time and radiation exposure, especially for pediatric patients. It supports both clinical and research endeavors and meets the rising need for advanced imaging solutions with its ultra-high sensitivity and spatial resolution, thereby improving operational efficiency in healthcare systems.

Global pain management devices market was valued at $7,245.4 million in 2025 and is growing at a CAGR of 5.4% during the forecast period (2026-2035). Rising chronic pain prevalence, especially neuropathic pain resulting from trauma and limb loss, is boosting demand for advanced pain management devices, as traditional pharmacological treatments often fail to deliver sustainable long-term relief, thereby reinforcing the need for device-based therapeutic solutions to support market growth. This shift toward targeted, non-pharmacological pain management approaches is increasingly reflected in the commercialization of advanced neuromodulation technologies. For instance, in July 2025, Neuros Medical announced the first commercial implantation of the Altius Direct Electrical Nerve Stimulation System, an FDA-approved device specifically for treating Chronic Post-Amputation Pain in lower limb amputees.